Stereotyped subset #1 chronic lymphocytic leukemia: A direct link between B-cell receptor structure, function, and patients' prognosis

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 74-82

  Del Giudice, Ilaria ^a   Chiaretti, Sabina ^a   Santangelo, Simona ^a   Tavolaro, Simona ^a   Peragine, Nadia ^a   Marinelli, Marilisa ^a   Ilari, Caterina ^a   Raponi, Sara ^a   Messina, Monica ^a   Nanni, Mauro ^a   Mauro, Francesca Romana ^a   Piciocchi, Alfonso ^b   Bontempi, Katia ^b   Rossi, Davide ^c   Gaidano, Gianluca ^c   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Foundation   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN M ANTIBODY; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENOMICS; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE STRUCTURE; MALE; MICROARRAY ANALYSIS; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CELL PROLIFERATION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84892890313     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23591     Document Type: Article

References (51)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
2. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
3. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene. Blood 2005;105:1678-1685.
4. Stamatopoulos K, Belessi C, Hadzidimitriou A, et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 2005;106:3575-3583.
5. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-525.
6. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007;109:259-270.
7. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524-1533.
8. Widhopf GF II, Goldberg CJ, Toy TL, et al. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 2008;111:3137-3144.
9. Bomben R, Dal Bo M, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: Results from an Italian multicentre study. Br J Haematol 2009;144:492-506.
10. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood 2012;119:4467-4475.
11. Rosén A, Murray F, Evaldsson C, et al. Antigens in chronic lymphocytic leukemia-Implications for cell origin and leukemogenesis. Semin Cancer Biol 2010;20:400-409.
12. Rossi D, Gaidano G. Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia. Haematologica 2010;95:1992-1995.
13. Thorsélius M, Kröber A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006;107:2889-2894.
14. Bomben R, Dal Bo M, Capello D, et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: An Italian multi center study. Blood 2007;109:2989-2998.
15. Ghia EM, Jain S, Widhopf GF II, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 2008;111:5101-5108.
16. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009;15:4415-4422.
17. Fält S, Merup M, Tobin G, et al. Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood 2005;106:681-689.
18. Marincevic M, Cahill N, Gunnarsson R, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica 2010;95:1519-1525.
19. Marincevic M, Mansouri M, Kanduri M, et al. Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Haematologica 2010;95:2072-2079.
20. Maura F, Cutrona G, Fabris S, et al. Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One 2011;6:e24313.
21. Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: Distinct gene expression profiles of potential pathogenetic significance in specific subsets of patients. Haematologica 2011;96:1644-1652.
22. Kanduri M, Marincevic M, Halldórsdóttir AM, et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 2012;7:1435-1442.
23. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
24. Del Giudice I, Mauro FR, De Propris MS, et al. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica 2011;96:626-630.
25. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012;26:1458-1461.
26. Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001;159:253-261.
27. Capello D, Guarini A, Berra E, et al. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. Leukemia 2004;18:1941-1947.
28. Ghia P, Stamatopoulos K, Belessi C, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007;21:1-3.
29. Del Giudice I, Chiaretti S, Tavolaro S, et al. Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases. Blood 2009;114:638-646.
30. Chiaretti S, Tavolaro S, Marinelli M, et al. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer 2011;50:263-274.
31. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-36.
32. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
33. Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010;28:2529-2537.
34. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008;112:782-792.
35. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
36. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness. Blood 2011;118:6904-6908.
37. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012;119:521-529.
38. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;119:2854-2862.
39. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300-309.
40. Paddock MN, Buelow BD, Takeda S, et al. The BRCT domain of PARP-1 is required for immunoglobulin gene conversion. PLoS Biol 2010;8:e1000428.
41. Bacalini MG, Tavolaro S, Peragine N, et al. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. Exp Hematol 2012;40:197-206.
42. Gougopoulou DM, Kiaris H, Ergazaki M, et al. Mutations and expression of the ras family genes in leukemias. Stem Cells 1996;14:725-729.
43. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471:235-239.
44. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111:3838-3848.
45. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008;14:665-674.
46. Chou MY, Hartvigsen K, Hansen LF, et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 2008;263:479-488.
47. Binder M, Léchenne B, Ummanni R, et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One 2010;5:e15992.
48. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: Implications for patient outcome and cell of origin. Blood 2010;115:3907-3915.
49. Binder M, Müller F, Jackst A, et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011;117:1891-1900.
50. Wiestner A. Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:88-96.
51. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94.